223 related articles for article (PubMed ID: 28221673)
1. Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis.
Wong SM; Stout NK; Punglia RS; Prakash I; Sagara Y; Golshan M
Cancer; 2017 Jul; 123(14):2609-2617. PubMed ID: 28221673
[TBL] [Abstract][Full Text] [Related]
2. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.
King TA; Pilewskie M; Muhsen S; Patil S; Mautner SK; Park A; Oskar S; Guerini-Rocco E; Boafo C; Gooch JC; De Brot M; Reis-Filho JS; Morrogh M; Andrade VP; Sakr RA; Morrow M
J Clin Oncol; 2015 Nov; 33(33):3945-52. PubMed ID: 26371145
[TBL] [Abstract][Full Text] [Related]
3. Lobular Carcinoma
Vora H; Kim S; Amersi F; Giuliano A; Chung A
Am Surg; 2017 Oct; 83(10):1040-1044. PubMed ID: 29391091
[TBL] [Abstract][Full Text] [Related]
4. The Pathologic Finding of Combined Lobular Carcinoma
Jean-Louis CJ; Masdon J; Smith B; Battles O; Dale P
Am Surg; 2017 May; 83(5):482-485. PubMed ID: 28541858
[TBL] [Abstract][Full Text] [Related]
5. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for women with lobular carcinoma in situ (LCIS).
Oppong BA; King TA
Oncology (Williston Park); 2011 Oct; 25(11):1051-6, 1058. PubMed ID: 22106556
[TBL] [Abstract][Full Text] [Related]
7. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ.
Wong SM; King T; Boileau JF; Barry WT; Golshan M
Ann Surg Oncol; 2017 Sep; 24(9):2509-2517. PubMed ID: 28455673
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.
Hershman D; Sundararajan V; Jacobson JS; Heitjan DF; Neugut AI; Grann VR
J Clin Oncol; 2002 Jan; 20(1):9-16. PubMed ID: 11773148
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy.
Xie ZM; Sun J; Hu ZY; Wu YP; Liu P; Tang J; Xiao XS; Wei WD; Wang X; Xie XM; Yang MT
Eur J Cancer; 2017 Sep; 82():6-15. PubMed ID: 28646773
[TBL] [Abstract][Full Text] [Related]
10. Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis.
Lester-Coll NH; Lee JM; Gogineni K; Hwang WT; Schwartz JS; Prosnitz RG
Breast Cancer Res Treat; 2015 Jul; 152(1):217-226. PubMed ID: 26062750
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma
Trivedi MS; Coe AM; Vanegas A; Kukafka R; Crew KD
Cancer Prev Res (Phila); 2017 Aug; 10(8):434-441. PubMed ID: 28611039
[TBL] [Abstract][Full Text] [Related]
12. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review.
De Brot M; Koslow Mautner S; Muhsen S; Andrade VP; Mamtani A; Murray M; Giri D; Sakr RA; Brogi E; King TA
Breast Cancer Res Treat; 2017 Sep; 165(2):411-420. PubMed ID: 28612228
[TBL] [Abstract][Full Text] [Related]
13. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis.
Portschy PR; Marmor S; Nzara R; Virnig BA; Tuttle TM
Ann Surg Oncol; 2013 Oct; 20(10):3240-6. PubMed ID: 23846782
[TBL] [Abstract][Full Text] [Related]
14. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Management of High-Risk Breast Lesions.
Thomas PS
J Natl Compr Canc Netw; 2018 Nov; 16(11):1391-1396. PubMed ID: 30442737
[TBL] [Abstract][Full Text] [Related]
16. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis.
Portschy PR; Kuntz KM; Tuttle TM
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25031308
[TBL] [Abstract][Full Text] [Related]
18. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
[TBL] [Abstract][Full Text] [Related]
19. Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?
Minami CA; Zabor EC; Gilbert E; Newman A; Park A; Jochelson MS; King TA; Pilewskie ML
Ann Surg Oncol; 2020 Jun; 27(6):1844-1851. PubMed ID: 31898097
[TBL] [Abstract][Full Text] [Related]
20. No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma.
Yu TJ; Liu YY; Hu X; Di GH
J Surg Oncol; 2018 Nov; 118(6):928-935. PubMed ID: 30311653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
